Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Dimethylfumarate induces apoptosis in human mast cells.
Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Episode 28 with Dr. Brenda Banwell on pediatric MS
Episode 2 with Dr. Barbara Koppel on recommendations for cannabis in MS
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Clarity Extension Study
Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis.
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
8th Annual Symposium on Glial-Neuronal Interactions
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Neurovascular and Immuno-Imaging Symposium
Live Webcast: Assessing the Potential Impact of New and Emerging Disease-Modifying Therapies on the Initial Treatment and Comprehensive Management of Multiple Sclerosis
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
The endocannabinoid system and multiple sclerosis.
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.

Pages